Getein Biotech, Inc

Shanghai Stock Exchange 603387.SS

Getein Biotech, Inc EBITDA for the year ending December 31, 2023: USD 60.13 M

Getein Biotech, Inc EBITDA is USD 60.13 M for the year ending December 31, 2023, a -36.61% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Getein Biotech, Inc EBITDA for the year ending December 31, 2022 was USD 94.85 M, a 15.43% change year over year.
Getein Biotech, Inc EBITDA for the year ending December 31, 2021 was USD 82.17 M, a 26.28% change year over year.
Getein Biotech, Inc EBITDA for the year ending December 31, 2020 was USD 65.07 M, a 5.03% change year over year.
Getein Biotech, Inc EBITDA for the year ending December 31, 2019 was USD 61.95 M, a 53.90% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shanghai Stock Exchange: 603387.SS

Getein Biotech, Inc

CEO	Mr. Gang Zhu
IPO Date	July 17, 2017
Location	China
Headquarters	No.9 Bofu Road
Employees	2,508
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Medical Instruments Pharmaceuticals

Description

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The company was founded in 2002 and is headquartered in Nanjing, China.

Key trends

Past 5 years